Responses
Spondyloarthritis
Original research
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
Compose a Response to This Article
Other responses
No responses have been published for this article.